Gilbert Harlan Daniels, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 36 | 2023 | 2360 | 2.870 |
Why?
|
Thyrotoxicosis | 8 | 2013 | 85 | 2.330 |
Why?
|
Carcinoma, Papillary, Follicular | 5 | 2016 | 59 | 1.910 |
Why?
|
Hyperthyroidism | 7 | 2023 | 292 | 1.820 |
Why?
|
Thyroiditis | 6 | 2020 | 86 | 1.620 |
Why?
|
Iodine Radioisotopes | 11 | 2023 | 1034 | 1.470 |
Why?
|
Thyroid Nodule | 11 | 2019 | 767 | 1.470 |
Why?
|
Calcitonin | 8 | 2017 | 328 | 1.380 |
Why?
|
Graves Disease | 7 | 2023 | 239 | 1.110 |
Why?
|
Adenocarcinoma, Follicular | 6 | 2021 | 326 | 0.830 |
Why?
|
Thyroidectomy | 11 | 2013 | 913 | 0.710 |
Why?
|
Thyroid Gland | 9 | 2023 | 1171 | 0.600 |
Why?
|
Carcinoma, Papillary | 8 | 2016 | 793 | 0.600 |
Why?
|
Hypothyroidism | 6 | 2009 | 667 | 0.570 |
Why?
|
Thyroxine | 8 | 2011 | 665 | 0.520 |
Why?
|
Hypoglycemic Agents | 6 | 2017 | 3109 | 0.520 |
Why?
|
Oncogene Fusion | 2 | 2021 | 84 | 0.510 |
Why?
|
Thyrotropin | 9 | 2012 | 834 | 0.470 |
Why?
|
Thyroid Diseases | 3 | 2013 | 385 | 0.410 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2014 | 374 | 0.410 |
Why?
|
Biopsy, Fine-Needle | 7 | 2014 | 1135 | 0.390 |
Why?
|
Pyrroles | 2 | 2008 | 1124 | 0.390 |
Why?
|
Ioxaglic Acid | 1 | 2011 | 29 | 0.380 |
Why?
|
Thyroiditis, Autoimmune | 1 | 2012 | 101 | 0.380 |
Why?
|
Indoles | 2 | 2008 | 1836 | 0.340 |
Why?
|
Biopsy, Needle | 5 | 2012 | 1622 | 0.330 |
Why?
|
Terminology as Topic | 1 | 2016 | 1542 | 0.320 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7454 | 0.310 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 558 | 0.300 |
Why?
|
Radiotherapy | 3 | 2013 | 1502 | 0.290 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2021 | 2059 | 0.270 |
Why?
|
Hypopituitarism | 1 | 2008 | 253 | 0.270 |
Why?
|
Lithium Compounds | 1 | 2008 | 226 | 0.260 |
Why?
|
Carotid Artery, Internal | 1 | 2008 | 440 | 0.260 |
Why?
|
Endocrine System Diseases | 1 | 2008 | 250 | 0.250 |
Why?
|
Adenoma | 1 | 2016 | 2159 | 0.250 |
Why?
|
Ultrasonography | 5 | 2020 | 6004 | 0.250 |
Why?
|
Arteriovenous Fistula | 1 | 2008 | 320 | 0.250 |
Why?
|
Thyroglobulin | 5 | 2014 | 111 | 0.240 |
Why?
|
Hyperprolactinemia | 2 | 2008 | 124 | 0.240 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2017 | 12252 | 0.230 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2021 | 343 | 0.230 |
Why?
|
Diabetes Complications | 1 | 2011 | 1320 | 0.220 |
Why?
|
Radiation Tolerance | 2 | 2015 | 476 | 0.210 |
Why?
|
Immunoglobulins, Thyroid-Stimulating | 2 | 2013 | 34 | 0.210 |
Why?
|
Mutation | 7 | 2021 | 30238 | 0.200 |
Why?
|
Radiopharmaceuticals | 3 | 2023 | 2735 | 0.200 |
Why?
|
Thyroiditis, Subacute | 1 | 2001 | 11 | 0.190 |
Why?
|
Contrast Media | 2 | 2013 | 5330 | 0.190 |
Why?
|
Humans | 73 | 2023 | 768166 | 0.190 |
Why?
|
Carcinoma, Medullary | 4 | 2011 | 116 | 0.180 |
Why?
|
Adenoma, Oxyphilic | 2 | 2021 | 152 | 0.180 |
Why?
|
Lithium Carbonate | 1 | 2001 | 179 | 0.180 |
Why?
|
Genetic Testing | 1 | 2013 | 3591 | 0.170 |
Why?
|
Amiodarone | 1 | 2001 | 217 | 0.160 |
Why?
|
Risperidone | 1 | 2000 | 383 | 0.150 |
Why?
|
Triiodothyronine | 3 | 2011 | 492 | 0.150 |
Why?
|
Female | 46 | 2017 | 397192 | 0.150 |
Why?
|
Antimanic Agents | 1 | 2001 | 524 | 0.150 |
Why?
|
Middle Aged | 33 | 2017 | 223492 | 0.140 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 872 | 0.140 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 3239 | 0.140 |
Why?
|
Pheochromocytoma | 2 | 2005 | 328 | 0.140 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 13014 | 0.130 |
Why?
|
Thyroid Function Tests | 2 | 2013 | 289 | 0.120 |
Why?
|
Male | 39 | 2017 | 364719 | 0.120 |
Why?
|
Virus Diseases | 1 | 2001 | 724 | 0.120 |
Why?
|
Hyperplasia | 2 | 2017 | 1151 | 0.120 |
Why?
|
Granuloma, Foreign-Body | 1 | 1995 | 41 | 0.120 |
Why?
|
Cell Differentiation | 3 | 2019 | 11669 | 0.120 |
Why?
|
Amylases | 1 | 2014 | 171 | 0.120 |
Why?
|
Thyroid Hormones | 2 | 2008 | 407 | 0.120 |
Why?
|
Pentagastrin | 2 | 2011 | 17 | 0.110 |
Why?
|
Carcinoma | 3 | 2015 | 2332 | 0.110 |
Why?
|
Aged | 26 | 2016 | 171504 | 0.110 |
Why?
|
Polytetrafluoroethylene | 1 | 1995 | 245 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 3187 | 0.110 |
Why?
|
Compartment Syndromes | 1 | 1995 | 159 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 18065 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3706 | 0.100 |
Why?
|
Adult | 26 | 2014 | 223646 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2019 | 572 | 0.100 |
Why?
|
Lipase | 1 | 2014 | 321 | 0.100 |
Why?
|
Ferrosoferric Oxide | 1 | 2013 | 348 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1778 | 0.100 |
Why?
|
Interferon-beta | 1 | 2013 | 349 | 0.100 |
Why?
|
Receptors, Thyrotropin | 1 | 2011 | 45 | 0.090 |
Why?
|
Double-Blind Method | 5 | 2017 | 12465 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2333 | 0.090 |
Why?
|
Receptors, Glucagon | 1 | 2011 | 90 | 0.090 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 2 | 2011 | 40 | 0.090 |
Why?
|
Adrenal Glands | 1 | 2013 | 557 | 0.090 |
Why?
|
Iodine | 1 | 2013 | 285 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1906 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10760 | 0.090 |
Why?
|
Adenocarcinoma | 3 | 2020 | 6395 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2830 | 0.080 |
Why?
|
Neck Dissection | 1 | 2011 | 201 | 0.080 |
Why?
|
Pituitary Function Tests | 1 | 2008 | 24 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2008 | 13676 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2013 | 14729 | 0.080 |
Why?
|
Obesity | 1 | 2011 | 13090 | 0.080 |
Why?
|
Prostheses and Implants | 1 | 1995 | 1276 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3620 | 0.070 |
Why?
|
Linear Models | 2 | 2015 | 5884 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4362 | 0.070 |
Why?
|
Sex Factors | 4 | 2015 | 10632 | 0.070 |
Why?
|
Antipsychotic Agents | 1 | 2000 | 3081 | 0.070 |
Why?
|
Adrenal Insufficiency | 1 | 2008 | 195 | 0.070 |
Why?
|
Adipose Tissue, Brown | 1 | 2012 | 776 | 0.070 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2227 | 0.060 |
Why?
|
Canada | 1 | 2011 | 2130 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4120 | 0.060 |
Why?
|
SEER Program | 2 | 2014 | 1444 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2017 | 39348 | 0.060 |
Why?
|
Reference Values | 3 | 2013 | 4938 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 1523 | 0.060 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2007 | 219 | 0.060 |
Why?
|
Autoantibodies | 1 | 2013 | 2121 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2016 | 15662 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2012 | 6847 | 0.060 |
Why?
|
History, 20th Century | 1 | 2013 | 2766 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2014 | 59629 | 0.060 |
Why?
|
Pregnancy Complications | 1 | 1999 | 2973 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20227 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2005 | 228 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2013 | 81762 | 0.050 |
Why?
|
Lipid Peroxides | 1 | 2023 | 74 | 0.050 |
Why?
|
Angiography | 1 | 2008 | 1597 | 0.050 |
Why?
|
Oxyphil Cells | 1 | 2023 | 56 | 0.050 |
Why?
|
Fermentation | 1 | 2023 | 143 | 0.050 |
Why?
|
Lymphatic Metastasis | 4 | 2012 | 2914 | 0.050 |
Why?
|
Calcium | 2 | 2013 | 5792 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10101 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2721 | 0.050 |
Why?
|
Quinazolines | 1 | 2008 | 1373 | 0.050 |
Why?
|
Iodide Peroxidase | 1 | 2003 | 295 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2016 | 65371 | 0.050 |
Why?
|
Body Mass Index | 2 | 2017 | 13053 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3239 | 0.040 |
Why?
|
Point Mutation | 1 | 2005 | 1596 | 0.040 |
Why?
|
Phosphotransferases | 1 | 2021 | 302 | 0.040 |
Why?
|
Young Adult | 5 | 2014 | 60066 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2013 | 3445 | 0.040 |
Why?
|
Bone Density | 1 | 2013 | 3573 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15454 | 0.040 |
Why?
|
Osmolar Concentration | 1 | 2000 | 657 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20760 | 0.040 |
Why?
|
Vitamin D | 1 | 2013 | 3311 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2008 | 2167 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2011 | 11244 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2697 | 0.040 |
Why?
|
Prolactin | 1 | 2000 | 627 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 127 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 30010 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2012 | 9419 | 0.040 |
Why?
|
Clozapine | 1 | 2000 | 509 | 0.030 |
Why?
|
Research Report | 1 | 2020 | 369 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2002 | 3474 | 0.030 |
Why?
|
Chorionic Gonadotropin | 1 | 1999 | 458 | 0.030 |
Why?
|
Goiter, Nodular | 1 | 1996 | 28 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3436 | 0.030 |
Why?
|
Time Factors | 3 | 2012 | 40218 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4912 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6669 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5446 | 0.030 |
Why?
|
Risk | 2 | 2004 | 9613 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1999 | 2000 | 0.030 |
Why?
|
Pakistan | 1 | 1995 | 299 | 0.030 |
Why?
|
Pregnancy | 2 | 2011 | 30256 | 0.030 |
Why?
|
Methimazole | 1 | 2013 | 41 | 0.030 |
Why?
|
Propylthiouracil | 1 | 2013 | 68 | 0.030 |
Why?
|
United States | 6 | 2014 | 73039 | 0.030 |
Why?
|
Mass Screening | 2 | 2007 | 5458 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 36743 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2013 | 72 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 751 | 0.030 |
Why?
|
Whole Body Imaging | 1 | 2014 | 284 | 0.030 |
Why?
|
Health Status | 1 | 2006 | 4091 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 4282 | 0.020 |
Why?
|
Barium Sulfate | 1 | 2012 | 180 | 0.020 |
Why?
|
Iopamidol | 1 | 2012 | 187 | 0.020 |
Why?
|
Postpartum Period | 1 | 1999 | 1198 | 0.020 |
Why?
|
Vocal Cord Paralysis | 1 | 1995 | 275 | 0.020 |
Why?
|
Neoplasms | 2 | 2017 | 22371 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2001 | 6316 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2002 | 8542 | 0.020 |
Why?
|
Ablation Techniques | 1 | 2013 | 255 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2011 | 338 | 0.020 |
Why?
|
Pain | 2 | 2006 | 5100 | 0.020 |
Why?
|
Prevalence | 3 | 2014 | 15869 | 0.020 |
Why?
|
Cytodiagnosis | 1 | 2013 | 452 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2048 | 0.020 |
Why?
|
Adolescent | 5 | 2014 | 89169 | 0.020 |
Why?
|
Child | 3 | 2013 | 80917 | 0.020 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2011 | 249 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3212 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1169 | 0.020 |
Why?
|
Incidental Findings | 1 | 2013 | 698 | 0.020 |
Why?
|
Fasting | 1 | 2014 | 1610 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2006 | 542 | 0.020 |
Why?
|
Drainage | 1 | 2013 | 1183 | 0.020 |
Why?
|
Pancreatitis | 1 | 2014 | 1087 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 1206 | 0.020 |
Why?
|
Melanoma | 1 | 2006 | 5706 | 0.020 |
Why?
|
Vanilmandelic Acid | 1 | 2005 | 17 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5863 | 0.020 |
Why?
|
Metanephrine | 1 | 2005 | 25 | 0.020 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 2005 | 25 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4755 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11101 | 0.010 |
Why?
|
Catecholamines | 1 | 2005 | 389 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2010 | 1791 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2005 | 766 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 2007 | 463 | 0.010 |
Why?
|
Preoperative Care | 1 | 2013 | 2258 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 1990 | 939 | 0.010 |
Why?
|
Cohort Studies | 3 | 2014 | 41754 | 0.010 |
Why?
|
Biopsy | 1 | 1996 | 6793 | 0.010 |
Why?
|
Quality of Life | 1 | 2006 | 13490 | 0.010 |
Why?
|
Codon | 1 | 2005 | 599 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7243 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6229 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1480 | 0.010 |
Why?
|
Neck | 2 | 2002 | 736 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2055 | 0.010 |
Why?
|
Risk Assessment | 3 | 2012 | 24315 | 0.010 |
Why?
|
Incidence | 2 | 2014 | 21538 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1996 | 3533 | 0.010 |
Why?
|
Sex Distribution | 1 | 2007 | 2278 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2389 | 0.010 |
Why?
|
Age Distribution | 1 | 2007 | 2873 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8890 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12840 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6498 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1992 | 2195 | 0.010 |
Why?
|
Kidney | 1 | 2014 | 7064 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12077 | 0.010 |
Why?
|
Pedigree | 1 | 2005 | 4539 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6211 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 6526 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13290 | 0.010 |
Why?
|
Cysts | 1 | 2002 | 685 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6514 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18412 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2016 | 11519 | 0.010 |
Why?
|
Survivors | 1 | 2006 | 2381 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 6983 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2005 | 4786 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22291 | 0.010 |
Why?
|
Stroke | 1 | 2016 | 9755 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2007 | 11095 | 0.010 |
Why?
|
Prospective Studies | 2 | 2013 | 54926 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15832 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15948 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1990 | 574 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1996 | 1281 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1990 | 238 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 1990 | 342 | 0.000 |
Why?
|
Child, Preschool | 1 | 2011 | 42669 | 0.000 |
Why?
|
Animals | 1 | 2001 | 169246 | 0.000 |
Why?
|
Immunoassay | 1 | 1990 | 746 | 0.000 |
Why?
|